公开(公告)号：US20210363130A1

公开(公告)日：2021-11-25

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  A61P35/00 ,  C07D401/12 ,  C07D405/14 ,  C07D405/12 ,  C07D213/84 ,  C07D403/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20170044132A1

公开(公告)日：2017-02-16

申请号：US15304623

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Douglas Robert CARY ,  Masanori OKANIWA ,  Yasuhiro HIRATA

IPC: C07D401/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D401/14 ,  C07D487/08 ,  C07D491/08 ,  C07D405/14 ,  C07D487/04 ,  C07D491/107 ,  C07D417/04 ,  C07D409/14 ,  C07D498/08

CPC classification number: C07D401/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D213/64 ,  C07D401/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

Abstract translation: （在该式中，符号如说明书中所定义）或其盐。

公开(公告)号：US20170037057A1

公开(公告)日：2017-02-09

申请号：US15304727

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masanori Okaniwa ,  Hiroshi BANNO ,  Takaharu HIRAYAMA ,  Douglas Robert CARY ,  Koji ONO ,  Naoki IWAMURA

IPC: C07D513/04

CPC classification number: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.

Abstract translation: （其中符号如说明书中所定义）或其盐。

公开(公告)号：US20190169166A1

公开(公告)日：2019-06-06

申请号：US16323863

申请日：2017-08-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jun FUJIMOTO ,  Xin LIU ,  Osamu KURASAWA ,  Terufumi TAKAGI ,  Douglas Robert CARY ,  Hiroshi BANNO ,  Yasutomi ASANO ,  Takuto KOJIMA

IPC: C07D401/12 ,  C07D239/42 ,  A61P35/00

Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20230117295A1

公开(公告)日：2023-04-20

申请号：US18075853

申请日：2022-12-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  C07D403/14 ,  C07D401/12 ,  C07D471/10 ,  C07D495/10 ,  C07D405/12 ,  C07D403/12 ,  C07D213/84 ,  C07D487/10 ,  C07D405/14 ,  A61P35/00

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.